Pharma Congress Market Analysis and Reports | Hungary Conference Series

Market Analysis - Pharma Congress 2017

The Organizing Committee invites all the participants across the globe to attend 12th World  Pharma Congress during October 16-18, 2017 Budapest, Hungary. Which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. Pharma Congress 2017 is a specially designed cluster Pharma conference. The main theme of these Pharma conferences is “Healthcare Policy-Makers And Payers: Key Concerns In Paradigm Shift Of Pharma Industry Trends’’. The Impact of developing and Marketing Drugs, its Registration & Approval” which covers a wide range of critically important sessions.

Over the last few decades a great deal of progress has  increased in research oriented approaches like improved technologies, developed infrastructures, and increased research in the field of Drug discovery, clinical trials, Drug delivery, preformulation studies and Nano-medicine in the pharmaceutical industry. To develop a new pharmaceutical formulation and to conduct clinical trials it cost at € 1,926 million in 2016. The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021. The new drug delivery system demand is increasing due to greater understanding of the functional benefits of excipients, pharmaceutical industry growth, and patent expiries of several popular drugs are positively impacting the overall growth of the market.

Revenue of the worldwide pharma market in 2016 was $1072bn. The global pharmaceutical industry was worth $10613bn in 2015. The generic pharma industry is currently worth an estimated $ 225 billion US and the largest four generic pharma companies worldwide by sales (Teva, Sandoz, Mylan, & Watson) account for nearly 50% of generic prescriptions in the US and 40% worldwide. The United Sates is a major hub for drug manufacturing and its market imports were valued over $86 billion in 2016, making the world’s largest importer of pharmaceuticals and $47 billion exports.

According to the 2015 EU Industrial R&D Investment Scoreboard the pharmaceutical and biotechnology sector amounts to 18.2% of total business R&D expenditure worldwide.On the other side Europe drug manufacturing is 225000 €millions and exports were 361500 €millions. Europe spent 31,500 €millions on R&D in 2015 while US spent 47,061€millions.However, considering the all aspects the European pharma market is expected to grow by 27% between 2015 and 2022. Germany is forecast to have highest increase in market value at € 11.4bn. Novartis is forecast to reduce its R&D spending, from $10.5bn in 2020 to only $9.2bn in 2022. Of the top 20, Celgene and Regeneron are forecast to grow their R&D expenses most rapidly, with R&D spend forecast to increase 11% per year until 2022. Overall, total R&D spends is expected to increase by 2.8% each year, reaching $182bn in 2022. Patient awareness regarding adverse drug events is stimulating global pharmacovigilance market growth by increase in number of National pharmacovigilance centers. Spain pharmacovigilance market size was valued over USD 230 million in 2015 and witness 10.2% CAGR from 2016 to 2024, to surpass USD 550 million by 2024.

Drug discovery technologies study includes Bio analytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Others comprising Epigenetics, Metabolomics, Combinatorial Chemistry, Synthetic Biology, Systems Biology and Nanotechnology. The global market value for these technologies market with an expected share of about 30% in 2015 valued at $18 billion followed by Bioanalytical Assays or instruments by about $14 billion. Innovative formulations are estimated to have contributed to 73%. Biopharmaceuticals have set new standards for popular drugs, which are traditionally defined as drugs that have $1 billion or more in annual sales; the top 15 biopharmaceutical products each profits annual revenue of more than $2 billion, with some drugs generating sales of more than $10 billion a year. In 2015 the top NMEs include Pfizer’s Ibrance, J&J’s Darzalex and Gilead’s Genvoya with a cumulative value of $32bn of sales expected in 2020. The increasing number of breakthrough therapy approvals also proves the ability of the pharmaceutical R&D to offer incremental benefits to targeted patient segments with larger unmet needs.

Pharmaceutical R&D Expenditure In Europe, USA and Japan (Millions Of National Currency Units*), 1990–2016

The market across US, Europe and Japan has accelerated by 7.5% in 2016.The graph illustrates the respective countries investments in R&D, Europe investing in a consisting manner along with other countries and competing with investment of USA. Japan’s investment is gradually increasing but less than other countries. The North American market (USA & Canada) remained the world’s largest market with a 48.7% share, well ahead of Europe and Japan.

European pharma market perspective by 2022

Europe is now facing increasing competition from emerging economies, rapid growth in the market and research environments from other countries. On the contrary, the sector facing real challenges in regulatory hurdles and escalating R&D costs, the sector has been severely hit by the impact of fiscal measures introduced by governments across much of Europe since 2010. The research–based pharmaceutical industry can play a critical role in restoring Europe to growth and ensuring future competitiveness in an advancing global economy. EU pharma market fragmentation resulted in a trade was estimated to amount of € 5,589 million (value at ex–factory prices) that benefit neither social security nor patients and deprived the drug development industry to fund new innovation in formulation. Parallel trade was estimated to amount to € 5,589 million. In 2015 North America accounted for 48.7% of world pharmaceutical sales compared with 22.2% for Europe. According to IMS Health data, 58% of sales of new drug discovery made during the period 2010–2015 were on the US market, compared with 23% on the European market. Europe is ensuring competitive growth along with other countries.  By 2022, products currently in drug development will account for 17% of sales in Europe. Europe is expected to show a 3% CAGR 2016-22, mainly driven by the launch of new products currently in development. The penetration of biotech products is set to increase from a 24% market share in 2015 to 29% in 2022. 

Pre-Clinical trial will witness a sustainable 10.3% growth, with target market size slated to exceed USD 84 million by 2024.  These studies are very critical and are mandatorily required before human clinical trials to collect safety and toxicity data in support of the new treatment. Phase III clinical trial should grow from over USD 492 million in 2015 to over USD 1,254 million by 2024, witnessing 10.9% CAGR from 2016 to 2024, owing to growing need for drug safety monitoring and evaluate drug efficacy based on risk-benefit ratio. Phase IV clinical trial market size was over USD 2.4 billion in 2015, growing at 10.9% from 2016 to 2024, owing to increasing drug safety concerns and growing public health awareness about adverse drug events. It aims at continuous safety surveillance through adverse drug monitoring as long as a product is marketed.

Despite of all parameters Europe has to meet parameters of Regulatory affairs and acts that lies at the basis of European pharmaceutical ethics and all of its intellectual property rights and its complications.